Cargando…
Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data
BACKGROUND: Little is known about the patterns of actual health care delivery of anti-vascular endothelial growth factor (VEGF) treatment in patients with age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion in Switzerland. The purpose of this study was to describe thes...
Autores principales: | Reich, Oliver, Bachmann, Lucas M, Faes, Livia, Böhni, Sophie C, Bittner, Mario, Howell, Jeremy P, Thiel, Michael A, Rapold, Roland, Schmid, Martin K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412486/ https://www.ncbi.nlm.nih.gov/pubmed/25960682 http://dx.doi.org/10.2147/RMHP.S80536 |
Ejemplares similares
-
Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis
por: Böhni, Sophie C., et al.
Publicado: (2015) -
Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
por: Blozik, Eva, et al.
Publicado: (2017) -
Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011
por: Huber, Carola A, et al.
Publicado: (2014) -
Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland
por: Reich, Oliver, et al.
Publicado: (2017) -
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
por: Schmid, Martin K., et al.
Publicado: (2015)